Intuitive Surgical Correction Reflects Growth Quality Concerns; Wait for Reacceleration

What happened

Intuitive Surgical's stock has fallen approximately 38% since our previous Hold rating, driven by valuation concerns and emerging structural headwinds that have shifted market focus away from its strong Q2 earnings beat. Despite revenue growing 19% and worldwide procedures up 16%, the market fixated on a slowdown in U.S. da Vinci procedure growth to 12% from 14% in the prior quarter, citing expiring ACA subsidies and weight loss drugs reducing bariatric demand. The DeepValue master report had already flagged this risk, rating the stock as WAIT with an attractive entry below $315, and the correction has brought the stock closer to that level but not below it. However, the underlying growth quality remains a question: trade-ins accounted for 144 of 468 placements, 54% of placements were leased, and China placements remained weak at just two systems. Until Q3 2026 evidence shows U.S. procedures re-accelerating above 12% and guidance holds or rises, the stock faces the risk of further multiple compression even with a strong balance sheet and franchise moat.

Implication

For investors, the 38% correction has partially priced in the concerns about U.S. procedure deceleration and competitive pressures, but the stock still trades at a premium to our $315 attractive entry. The next 3-6 months are critical: if Q3 U.S. da Vinci procedure growth fails to recover above 12%, the stock could de-rate further toward our bear case of $285. Conversely, if procedures re-accelerate and guidance is maintained, the stock could recover toward our base case of $350. Patience is warranted until the next quarterly report provides clarity on whether the slowdown is temporary or structural. A disciplined entry below $315 offers a more favorable risk-adjusted return given the installed-base moat and cash generation.

Thesis delta

The 38% correction has changed the risk-reward equation from negative to balanced, but it has not altered the core thesis that the stock requires observable proof of U.S. procedure re-acceleration. The shift is that the downside risk has been partially realized, making the stock more interesting for patient investors, but we still require higher conviction from upcoming data before moving from WAIT to BUY.